Wedbush restated their neutral rating on shares of Omeros (NASDAQ:OMER) in a research report sent to investors on Monday, RTT News reports. Wedbush currently has a $18.00 target price on the biopharmaceutical company’s stock.
A number of other research firms have also commented on OMER. BidaskClub lowered shares of Vertex Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, July 9th. HC Wainwright set a $55.00 price objective on shares of Acer Therapeutics and gave the stock a buy rating in a research note on Tuesday, May 28th. ValuEngine lowered shares of Yirendai from a sell rating to a strong sell rating in a research note on Wednesday, June 26th. Zacks Investment Research raised shares of DLH from a sell rating to a hold rating in a research note on Tuesday, July 9th. Finally, Cantor Fitzgerald reaffirmed a buy rating and issued a $71.00 price objective on shares of ExlService in a research note on Monday, May 6th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of Hold and a consensus target price of $25.80.
Shares of NASDAQ:OMER opened at $15.45 on Monday. The company has a market capitalization of $750.09 million, a PE ratio of -6.96 and a beta of 3.04. Omeros has a 1-year low of $10.30 and a 1-year high of $27.00. The business’s 50 day simple moving average is $16.23.
Omeros (NASDAQ:OMER) last posted its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.04). The company had revenue of $21.80 million for the quarter, compared to analysts’ expectations of $23.18 million. During the same period last year, the company earned ($0.62) earnings per share. The business’s revenue for the quarter was up 1271.1% on a year-over-year basis. Analysts expect that Omeros will post -1.68 EPS for the current year.
A number of hedge funds have recently added to or reduced their stakes in OMER. Millennium Management LLC lifted its position in Omeros by 844.8% in the 4th quarter. Millennium Management LLC now owns 1,112,584 shares of the biopharmaceutical company’s stock worth $12,394,000 after buying an additional 994,829 shares in the last quarter. D. E. Shaw & Co. Inc. lifted its position in Omeros by 49.5% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,912,244 shares of the biopharmaceutical company’s stock worth $21,303,000 after buying an additional 632,840 shares in the last quarter. First Trust Advisors LP purchased a new stake in Omeros in the 4th quarter worth approximately $879,000. SG Americas Securities LLC lifted its position in Omeros by 68.5% in the 1st quarter. SG Americas Securities LLC now owns 144,444 shares of the biopharmaceutical company’s stock worth $2,509,000 after buying an additional 58,731 shares in the last quarter. Finally, Tibra Equities Europe Ltd purchased a new stake in Omeros in the 1st quarter worth approximately $771,000. Institutional investors own 52.12% of the company’s stock.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.